A Pilot Study to Assess the Preliminary Efficacy of EDTA Eye Drops on Band Keratopathy

NCT ID: NCT03985371

Last Updated: 2022-01-05

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: EARLY_PHASE1
• Total Enrollment: 3 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-06-29
• Study Completion Date: 2021-09-30

Brief Summary

The objective of this study is to collect preliminary efficacy and safety data on the use of EDTA EYE Drops (EED) on subjects during an episode of band keratopathy (BK).

Detailed Description

This study is an open-label, pilot study of up to 6 subjects with documented BK.

This study has 2 phases: In Phase 1 subjects must be willing to return to the clinic for evaluation of safety and BK symptoms during the treatment period of 6 months (Days 7, 60, 120, 180) and for follow up at Months 9 and 12. In Phase 2 subjects must be willing to return to the clinic at 18 and 24 months post-first dose for a final evaluation.

On Day 1 of the study, potential subjects will be screened and if they meet entry requirements they will be enrolled in the study.

Once enrolled, subjects will be assessed for baseline symptoms and visual acuity, have corneal photographs taken of their affected eye, dispensed EED and instructed to use it for 2 times/day for 6 months in the eye with BK. They will be dosed for the first time in the clinic in order to show them how to consistently use the drops. Subjects will also be given a diary card to record potential adverse events and pain levels (with the first level being noted in the clinic), dismissed from the clinic and reminded to return on Day 7 for assessment of tolerability and safety.

At each subsequent visit (Days 7, 60, 120, 180) the subject will be asked to rate their pain at the time of the visit on a pain analog scale. Their diary card will be reviewed for potential adverse events (AEs) and use of EED will be assessed for technique and compliance. Between visits, subjects will be called every 4 weeks by a member of the study site team to assess potential AEs and dosing compliance.

Additionally, the subject or their caregiver will check the treated eye on a weekly basis and note whether the calcific bands are still present on the diary card. When bands have disappeared, subject will notify the eye clinic and schedule a return visit to obtain corneal photographs and visual acuity test. This may occur outside the planned study visits.

On Day 180, subjects will present at the clinic to return their diary card and unused study product. They will be asked to return to the clinic on Days 270 and 360 for assessment of their visual acuity, pain, corneal photography of the affected eye and potential AEs.

Day 360 will be considered the end of study phase 1. Phase 2 of the study includes long term follow up for possible recurrence. Subjects will be scheduled to return for follow-up visits at months 18 and 24 for assessment of visual acuity and recurrence of BK symptoms.

Conditions

Corneal Dystrophy, Band-Shaped

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Drops Used

Group Type: EXPERIMENTAL

EDTA Eye Drops

Intervention Type: DRUG

One drop in the Band Keratopathy affected eye only, two times per day for six months.

Interventions

EDTA Eye Drops

One drop in the Band Keratopathy affected eye only, two times per day for six months.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Understand the requirements of the study and provide informed consent prior to undergoing any study-related procedures

2. Be between the ages of 40 and 80 years old, inclusive

3. Have a documented BK diagnosis

4. Be willing and able to comply with protocol-specified dosing, visits to the clinic and tracking of symptoms

Exclusion Criteria

1. Use other therapies for BK including amniotic membrane or conjunctival grafts.

2. Have other co-morbidities that may confound the safety and efficacy measurements for this study.

3. Have participated in any other clinical trial within 30 days prior to enrollment.

4. Have any condition, abnormality or situation at Baseline that in the opinion of the Principal Investigator may preclude the subject's ability to comply with study requirements, including completion of the study

• Minimum Eligible Age: 40 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Livionex Inc.

INDUSTRY

Sponsor Role: collaborator

University of Rochester

OTHER

Sponsor Role: lead

Responsible Party

James V. Aquavella, MD

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

University of Rochester

Rochester, New York, United States

Countries

United States

Other Identifiers

3712

Identifier Type: -

Identifier Source: org_study_id